Becton, Dickinson stock
BDXNYSEBecton, Dickinson and Company, HealthcareISIN US0758871091
59Score 59 out of 100, Neutral
Price and trend
85 / 100
Price history
+44% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 70).
The price is at its 52-week high. Largest decline in 20 years: 42% (July 2023 to May 2025).
Chart figures for advanced users
- SMA 50$189.76
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$167.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$140.71
- The lowest closing price of the last twelve months.
- Resistance$215.25
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Becton, Dickinson and Company belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $58.43B, is number 3 of 44 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $19.46B (down 10.9% year on year) and earnings of $1.15B (down 31.7%).
- For fiscal 2027, analysts expect on average revenue of $19.69B (up 1.2%) and adjusted earnings per share of $13.25 (up 0.4%).
Show more
- MEQIRI Score 59 out of 100 (Neutral): rank 282 of 714 in Healthcare, median 53.
- The P/E is 39.5 (Medical (Instruments & Supplies) median 34.8, own median of recent years 32.2).
- Our model puts fair value at $184.02, with the price 17% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 43 years.
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 76
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis, while valuation and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $141.56 and expensive above $262.89 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $179.38 (cash-flow model) and $188.66 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $169.17, at 7.8% it would be $206.29.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue fell 10.9% on the prior year. Revenue has grown solidly since 2007, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 47%, operating 12%, net not measured.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 8 Feb 2027in 88 days
- Last reported
- 5 Nov 2026EPS reported $4.15 (expected $4.07)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $13.250.0%
- Revenue
- $19.69B0.0%
- Earnings per share
- $14.160.0%
- Revenue
- $20.46B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.6%Guidance was raised to revenue growth toward the high end of the low single digit range and EPS of $12.62 to $12.72 with a higher midpoint.
“Given our Q3 performance and continued productivity through BD Excellence, we are increasing the midpoint of our adjusted EPS guidance and updating our range to $12.62 to $12.72.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $2.66M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Polen Thomas E JrSale
5 Nov 2026, Chairman, CEO and President
- Shares
- 2,993
- Price
- $210.00
- Value
- $628,530
- Feld MichaelSale
26 Oct 2026, EVP, Chief Revenue Officer
- Shares
- 76
- Price
- $198.13
- Value
- $15,058
- Feld MichaelSale
28 Sept 2026, EVP, Chief Revenue Officer
- Shares
- 76
- Price
- $183.70
- Value
- $13,961
Show 9 more
- Feld MichaelSale
26 Aug 2026, EVP, Chief Revenue Officer
- Shares
- 165
- Price
- $188.49
- Value
- $31,101
- Polen Thomas E JrSale
13 Aug 2026, Chairman, CEO and President
- Shares
- 4,152
- Price
- $185.00
- Value
- $768,120
- Goette RolandSale
11 Aug 2026, EVP and President, EMEA
- Shares
- 2,438
- Price
- $180.84
- Value
- $440,888
- Feld MichaelSale
27 Jul 2026, EVP, Chief Revenue Officer
- Shares
- 75
- Price
- $157.13
- Value
- $11,785
- Feld MichaelSale
26 Jun 2026, EVP, Chief Revenue Officer
- Shares
- 75
- Price
- $152.80
- Value
- $11,460
- Garrison Michael DavidSale
24 Jun 2026, EVP & Pres Med.Essntl&BioPharm
- Shares
- 1,100
- Price
- $145.66
- Value
- $160,226
- Garrison Michael DavidSale
10 Jun 2026, EVP & Pres Med.Essntl&BioPharm
- Shares
- 1,100
- Price
- $151.48
- Value
- $166,628
- Polen Thomas E JrSale
1 Jun 2026, Chairman, CEO and President
- Shares
- 2,764
- Price
- $146.35
- Value
- $404,511
- Feld MichaelSale
26 May 2026, EVP, Chief Revenue Officer
- Shares
- 75
- Price
- $147.35
- Value
- $11,051
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Becton, Dickinson
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Intuitive SurgicalISRG $155.83B76
- EssilorLuxotticaEL.PA $93.35B62
- HOYA7741.T $50.12B76
- MedlineMDLN $37.04B55
- ResMedRMD $33.55B84
- West Pharmaceutical ServicesWST $28.76B78
- Sartorius Stedim BiotechDIM.PA $24.55B58
- Straumann HoldingSTMN.SW $20.49B78
ETFs that hold Becton, Dickinson
Held by 113 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.60% | 0.49% | €318.39M |
| State Street SPDR S&P U.S. Dividend Aristocrats UCITS ETF (Dist)SPYD | 1.11% | 0.35% | €3.62B |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF hEUR accUBUW | 0.93% | 0.28% | €127.84M |
Show 5 more
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.87% | 0.15% | €592.11M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.84% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.83% | 0.15% | €3.27B |
| UBS Factor MSCI USA Low Volatility UCITS ETF hEUR accUBUV | 0.69% | 0.21% | €64.75M |
| iShares MSCI World Value Factor Advanced UCITS ETFCBUI | 0.67% | 0.25% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Jul 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.